The Experts below are selected from a list of 1773 Experts worldwide ranked by ideXlab platform
Hiroyoshi Tanaka - One of the best experts on this subject based on the ideXlab platform.
-
retraction note to ramosetron vs Granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy
Canadian Journal of Anaesthesia-journal Canadien D Anesthesie, 2013Co-Authors: Yuhji Saitoh, Hiroyoshi TanakaAbstract:To compare the efficacy of ramosetron with Granisetron for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy. In a randomized, double-blind study, 80 female inpatients received 3 mg Granisetron or 0.3 mg ramosetroniv (n=40 of each) at the completion of surgery The standardized anesthetic included isoflurane and nitrous oxide in oxygen. Complete response, defined as no PONV during the first 24 hr (0–24 hr) after anesthesia was 85% with Granisetron and 93% with ramosetron, respectively (P=0.241); the corresponding incidence during the next 24 hr (24–48 hr) after anesthesia was 63% and 90% (P=0.004). No clinically important adverse events due to the study drug were observed in any of the groups. Ramosetron was more effective than Granisetron for prevention of PONV during 0–48 hr after anesthesia for laparoscopic cholecystectomy.
-
benefits and risks of Granisetron versus ramosetron for nausea and vomiting after breast surgery a randomized double blinded placebo controlled trial
American Journal of Therapeutics, 2004Co-Authors: Hiroyoshi Tanaka, Tsuneo KawasakiAbstract:Women undergoing general anesthesia for breast surgery are at particular risk of postoperative nausea and vomiting. In a randomized, double-blinded, placebo-controlled trial, 90 patients scheduled for breast surgery, aged 33-63 years, received intravenously placebo, 3 mg Granisetron, or 0.3 mg ramosetron (n = 30 of each) at the end of surgical procedure. A standard general anesthetic technique and postoperative analgesia were used. Emetic episodes and safety assessment were performed during 0-24 hours and 24-48 hours after anesthesia. The rate of patients experiencing emetic symptoms (nausea, retching, vomiting) 0-24 hours after anesthesia was 17% with Granisetron (P = 0.013) and 10% with ramosetron (P = 0.002) compared with placebo (47%); the corresponding rate 24-48 hours after anesthesia was 27% (P = 0.032) and 7% (P = 0.001), compared with placebo (53%). In the 24-48 hours after anesthesia, there were fewer emetic episodes in patients who had received ramosetron than in those who had received Granisetron (P = 0.039). The severity of nausea was less in patients receiving ramosetron than in those receiving Granisetron (P = 0.044). Zero to 24 hours after anesthesia, no difference in the rate of patients having emetic symptoms and the severity of nausea was observed between the Granisetron and ramosetron groups. The most common reported adverse events were headache and dizziness, and there were no difference in the incidence of adverse events due to the study drug among the 3 groups. In conclusion, prophylactic therapy with ramosetron is more effective than that with Granisetron for the long-term prevention of postoperative nausea and vomiting in women undergoing general anesthesia for breast surgery.
-
Granisetron versus Granisetron dexamethasone combination for the treatment of nausea retching and vomiting after major gynecologic surgery a randomized double blind study
Clinical Therapeutics, 2003Co-Authors: Yoshitaka Fujii, Hiroyoshi TanakaAbstract:Abstract Granisetron, a selective 5-hydroxytryptamine 3 antagonist, is effective for the treatment of patients with postoperative nausea and vomiting. Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. This study compared the efficacy of Granisetron alone with Granisetron/dexamethasone combination for the treatment of nausea and vomiting after major gynecologic surgery. In this randomized, double-blind study, patients who were experiencing emetic symptoms during 0 to 3 hours after the end of anesthesia administration received Granisetron 40 μg/kg IV either alone or in combination with dexamethasone 8 mg. Patients then were observed for 24 hours after study drug administration, with emetic episodes recorded and tolerability assessments performed by nursing staff blinded to treatment. A total of 120 women were enrolled (n = 60 in each treatment group; mean [SD] age in the Granisetron group, 44 [9] years [range, 23–63 years]; combination group, 45 [8] years [range, 21–65 years]). No significant differences in patient demographic characteristics were found between the 2 treatment groups. However, the percentage of patients free of emetic symptoms (nausea, retching, vomiting) was higher in the Granisetron/dexamethasone combination group than in the Granisetron group (95.0% and 80.0%, respectively; P = 0.012). No clinically serious adverse events attributed to the study drugs were observed in either group. In this study, the Granisetron/dexamethasone combination was more effective than was Granisetron alone for the management of nausea and vomiting during 0 to 3 hours after anesthesia in women undergoing major gynecologic surgery.
-
comparison of Granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy
Clinical Therapeutics, 2002Co-Authors: Hiroyoshi TanakaAbstract:Abstract Background: Postoperative nausea and vomiting (PONV) are common after thyroidectomy. Granisetron, a selective 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonist, is more effective than the traditional antiemetics droperidol and metoclopramide for the prevention of PONV after thyroidectomy. Ramosetron, another new selective antagonist of 5-HT 3 receptor, has been shown to have more potent and longer-acting properties than Granisetron against cisplatin-induced emesis in ferrets. Objective: This study was undertaken to compare the efficacy and tolerability of Granisetron and ramosetron for the prevention of PONV after thyroidectomy. Methods: In this randomized, double-blind study, patients received Granisetron 3 mg or ramosetron 0.3 mg intravenously at the end of surgery. A standard general anesthetic technique and postoperative analgesia were used. Emetic episodes and safety were assessed during the first 24 hours and the second 24 hours after anesthesia. Results: Eighty patients (15 men, 65 women) aged 33 to 58 years were included in the study. Each study group consisted of 40 patients. There were no differences between groups with regard to patient demographics. The percentage of patients who were emesis free (no nausea, no retching, no vomiting) 0 to 24 hours after anesthesia was 83% (33 of 40) with Granisetron and 88% (35 of 40) with ramosetron; the corresponding rates 24 to 48 hours after anesthesia were 63% (25 of 40) and 90% (36 of 40), respectively ( P = 0.004). The safety profile of the two 5-HT 3 receptor antagonists was comparable, as no clinically serious adverse effects caused by the study drug were observed in either of the groups. Conclusions: Prophylactic antiemetic therapy with ramosetron was comparable to therapy with Granisetron for the prevention of PONV 0 to 24 hours after anesthesia in patients who underwent thyroidectomy; 24 to 48 hours after anesthesia, ramosetron was more effective than Granisetron for prophylaxis against PONV in this population.
-
ramosetron compared with Granisetron for the prevention of vomiting following strabismus surgery in children
British Journal of Ophthalmology, 2001Co-Authors: Hiroyoshi Tanaka, Mutsuko ItoAbstract:BACKGROUND/AIMS—Postoperative vomiting occurs frequently after strabismus surgery in children. Granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, is effective for the prevention of vomiting following paediatric strabismus surgery. Ramosetron, another new antagonist of 5-hydroxytryptamine type 3 receptor, has more potent and longer acting properties than Granisetron against cisplatin induced emesis. This study was undertaken to compare the efficacy and safety of Granisetron and ramosetron for the prevention of vomiting following strabismus surgery in children. METHODS—In a randomised, double blinded manner 80 children, aged 4-10 years, received intravenously Granisetron 40 µg/kg or ramosetron 6 µg/kg (n=40 each) at the end of surgery. A standard general anaesthetic technique and postoperative analgesia were used. Emetic episodes and safety assessment were performed during the first 24 hours and the next 24 hours after anaesthesia. RESULTS—The percentage of patients who were emesis free during 0-24 hours after anaesthesia was 85% with Granisetron and 90% with ramosetron, respectively (p = 0.369); the corresponding rate during 24-48 hours after anaesthesia was 70% and 95% (p = 0.003). No clinically serious adverse events caused by the study drug were observed in any of the groups. CONCLUSION—Prophylactic antiemetic therapy with ramosetron is comparable with Granisetron for the prevention of vomiting during 0-24 hours after anaesthesia in children undergoing strabismus surgery. During 24-48 hours after anaesthesia, ramosetron is more effective than Granisetron for prophylaxis against postoperative vomiting.
Hidenori Toyooka - One of the best experts on this subject based on the ideXlab platform.
-
Granisetron dexamethasone combination for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy
Survey of Anesthesiology, 2000Co-Authors: Yoshitaka Fujii, Hiroyoshi Tanaka, Y Saitoh, Hidenori ToyookaAbstract:Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. This study was undertaken to evaluate the efficacy of Granisetron/dexamethasone combination for preventing postoperative nausea and vomiting (PONV) after lapIaroscopic cholecystectomy (LC). In a prospective, randomized, double-blind manner, 120 patients (83 females), aged 25-65 years, were assigned to receive Granisetron 40 microg kg-1 alone or Granisetron 40 microg kg-1 plus dexamethasone 8 mg (n=60 of each) intravenously immediately before the induction of anaesthesia. A standardized general anaesthetic procedure and postoperative analgesia were used. A complete response, defined as no PONV and no need for another rescue antiemetic, during 0-3 h after anaesthesia was 83% with Granisetron and 98% with Granisetron plus dexamethasone, respectively (P=0.008); the corresponding incidence during 3-24 h after anaesthesia was 83% and 98% (P=0.008). No clinically important adverse events were observed in any of the group. In conclusion, prophylactic therapy with Granisetron/dexamethasone combination is more effective than Granisetron alone for the prevention of PONV after LC.
-
comparison of ramosetron and Granisetron for preventing postoperative nausea and vomiting after gynecologic surgery
Anesthesia & Analgesia, 1999Co-Authors: Yoshitaka Fujii, Yuhji Saitoh, Hiroyoshi Tanaka, Hidenori ToyookaAbstract:UNLABELLED In a prospective, randomized, double-blinded study, we evaluated the efficacy of Granisetron and ramosetron for preventing postoperative nausea and vomiting (PONV) in major gynecologic surgery. One hundred twenty patients, ASA physical status I or II, aged 23-65 yr, received i.v. Granisetron 2.5 mg or ramosetron 0.3 mg (n = 60 each) at the end of surgery. A standard general anesthetic technique and postoperative analgesia were used. The incidence of a complete response, defined as no PONV and no need for another rescue medication, 0-3 h after anesthesia was 87% with Granisetron and 90% with ramosetron; the corresponding incidence 3-24 h after anesthesia was 85% and 90%; the corresponding incidence 24-48 h after anesthesia was 70% and 92% (P < 0.05). No clinically serious adverse events due to the drugs were observed in any of the groups. In conclusion, prophylactic therapy with ramosetron is more effective than Granisetron for the longterm prevention of PONV after major gynecologic surgery. IMPLICATIONS We compared the efficacy of Granisetron and ramosetron for preventing postoperative nausea and vomiting in major gynecologic surgery. Prophylactic therapy with ramosetron was more effective than Granisetron for preventing postoperative nausea and vomiting 24-48 h after anesthesia.
-
prophylactic antiemetic therapy with Granisetron dexamethasone combination in women undergoing breast surgery
Acta Anaesthesiologica Scandinavica, 1998Co-Authors: Yoshitaka Fujii, Hiroyoshi Tanaka, Hidenori ToyookaAbstract:Background: Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. This study was undertaken to evaluate the efficacy of Granisetron-dexamethasone combination for the prevention of postoperative nausea and vomiting (PONV) in female patients undergoing general anaesthesia for breast surgery. Methods: In a randomized, double-blind manner, 135 ASA I patients, aged 40–65 years, were assigned to receive placebo (saline), Granisetron 40 μg · kg−1 or Granisetron 40 μg · kg−1 plus dexamethasone 8 mg i.v. (n=45 of each) immediately before the induction of anaesthesia. A standard general anaesthetic technique and postoperative analgesia were used. The PONV and safety assessments were performed continuously during the first 3 h (0–3 h) and the next 21 h (3–24 h) after anaesthesia. Results: A complete response, defined as no PONV and no administration of rescue antiemetic medication, during 0–3 h after anaesthesia was 51%, 82% and 96% in patients who had received placebo, Granisetron and Granisetron-dexamethasone combination, respectively; the corresponding incidence during 3–24 h after anaesthesia was 56%, 84% and 98% (P<0.05; overall Fisher's exact probability test). No clinically important adverse events were observed in any of the groups. Conclusion: Prophylactic use of Granisetron-dexamethasone combination is more effective than Granisetron alone for the prevention of PONV after breast surgery.
-
anti emetic efficacy of prophylactic Granisetron droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy a randomized double blind placebo controlled trial
European Journal of Anaesthesiology, 1998Co-Authors: Yoshitaka Fujii, Hiroyoshi Tanaka, Y Saitoh, Hidenori ToyookaAbstract:This study evaluates the prophylactic anti-emetic efficacy of Granisetron, droperidol and metoclopramide, for the prevention of post-operative nausea and vomiting in female patients undergoing elective laparoscopic cholecystectomy. The patients were randomly assigned to one of four groups ( n =30 for each group): Granisetron 3 mg, droperidol 1.25 mg, metoclopramide 10 mg and placebo (saline). These medications were given immediately before the induction of anaesthesia. During the first 24 h after an-aesthesia, the incidence of post-operative nausea and vomiting was 13, 30, 33 and 37% after administration of Granisetron, droperidol, metoclopramide and placebo, respectively ( P >0.05, overall Fisher's exact probability test). No clinically important adverse effects were observed in either group. Our results suggest that Granisetron is a better anti-emetic than droperidol or metoclopramide for the prevention of post-operative nausea and vomiting after laparoscopic cholecystectomy when compared with a placebo.
-
the effects of dexamethasone on antiemetics in female patients undergoing gynecologic surgery
Anesthesia & Analgesia, 1997Co-Authors: Yoshitaka Fujii, Hiroyoshi Tanaka, Hidenori ToyookaAbstract:UNLABELLED This randomized, double-blind study compared the effects of dexamethasone plus either droperidol, metoclopramide, or Granisetron with each antiemetic alone for preventing postoperative nausea and vomiting (PONV) in 270 female patients undergoing general anesthesia for major gynecological surgery. Patients were randomly assigned to receive either droperidol 1.25 mg (Group D1, n = 45), droperidol 1.25 mg plus dexamethasone 8 mg (Group D2, n = 45), metoclopramide 10 mg (Group M1, n = 45), metoclopramide 10 mg plus dexamethasone 8 mg (Group M2, n = 45), Granisetron 40 micrograms/kg (Group G1, n = 45), or Granisetron 40 micrograms/kg plus dexamethasone 8 mg (Group G2, n = 45) immediately before the induction of anesthesia. A standard general anesthetic technique and postoperative analgesia were used throughout the study. Complete response, defined as no PONV and no administration of rescue antiemetic medication during the first 24 h after anesthesia, was 49% in Group D1, 60% in Group D2 (P = 0.199 versus Group D1), 51% in Group M1, 62% in Group M2 (P = 0.198 versus Group M1), 80% in Group G1, and 96% in Group G2 (P = 0.025 versus Group G1). Our results suggest that dexamethasone enhances the antiemetic efficacy of Granisetron but does not potentiate the other antiemetics-droperidol and metoclopramide-in female patients undergoing major gynecological surgery. IMPLICATIONS We compared the efficacy of dexamethasone plus three different antiemetics-droperidol, metoclopramide, and Granisetron-for the prevention of nausea and vomiting after gynecologic surgery. The Granisetron-dexamethasone combination was the most effective for preventing post-operative emetic symptoms.
Yoshitaka Fujii - One of the best experts on this subject based on the ideXlab platform.
-
Granisetron versus Granisetron dexamethasone combination for the treatment of nausea retching and vomiting after major gynecologic surgery a randomized double blind study
Clinical Therapeutics, 2003Co-Authors: Yoshitaka Fujii, Hiroyoshi TanakaAbstract:Abstract Granisetron, a selective 5-hydroxytryptamine 3 antagonist, is effective for the treatment of patients with postoperative nausea and vomiting. Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. This study compared the efficacy of Granisetron alone with Granisetron/dexamethasone combination for the treatment of nausea and vomiting after major gynecologic surgery. In this randomized, double-blind study, patients who were experiencing emetic symptoms during 0 to 3 hours after the end of anesthesia administration received Granisetron 40 μg/kg IV either alone or in combination with dexamethasone 8 mg. Patients then were observed for 24 hours after study drug administration, with emetic episodes recorded and tolerability assessments performed by nursing staff blinded to treatment. A total of 120 women were enrolled (n = 60 in each treatment group; mean [SD] age in the Granisetron group, 44 [9] years [range, 23–63 years]; combination group, 45 [8] years [range, 21–65 years]). No significant differences in patient demographic characteristics were found between the 2 treatment groups. However, the percentage of patients free of emetic symptoms (nausea, retching, vomiting) was higher in the Granisetron/dexamethasone combination group than in the Granisetron group (95.0% and 80.0%, respectively; P = 0.012). No clinically serious adverse events attributed to the study drugs were observed in either group. In this study, the Granisetron/dexamethasone combination was more effective than was Granisetron alone for the management of nausea and vomiting during 0 to 3 hours after anesthesia in women undergoing major gynecologic surgery.
-
Granisetron dexamethasone combination for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy
Survey of Anesthesiology, 2000Co-Authors: Yoshitaka Fujii, Hiroyoshi Tanaka, Y Saitoh, Hidenori ToyookaAbstract:Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. This study was undertaken to evaluate the efficacy of Granisetron/dexamethasone combination for preventing postoperative nausea and vomiting (PONV) after lapIaroscopic cholecystectomy (LC). In a prospective, randomized, double-blind manner, 120 patients (83 females), aged 25-65 years, were assigned to receive Granisetron 40 microg kg-1 alone or Granisetron 40 microg kg-1 plus dexamethasone 8 mg (n=60 of each) intravenously immediately before the induction of anaesthesia. A standardized general anaesthetic procedure and postoperative analgesia were used. A complete response, defined as no PONV and no need for another rescue antiemetic, during 0-3 h after anaesthesia was 83% with Granisetron and 98% with Granisetron plus dexamethasone, respectively (P=0.008); the corresponding incidence during 3-24 h after anaesthesia was 83% and 98% (P=0.008). No clinically important adverse events were observed in any of the group. In conclusion, prophylactic therapy with Granisetron/dexamethasone combination is more effective than Granisetron alone for the prevention of PONV after LC.
-
comparison of ramosetron and Granisetron for preventing postoperative nausea and vomiting after gynecologic surgery
Anesthesia & Analgesia, 1999Co-Authors: Yoshitaka Fujii, Yuhji Saitoh, Hiroyoshi Tanaka, Hidenori ToyookaAbstract:UNLABELLED In a prospective, randomized, double-blinded study, we evaluated the efficacy of Granisetron and ramosetron for preventing postoperative nausea and vomiting (PONV) in major gynecologic surgery. One hundred twenty patients, ASA physical status I or II, aged 23-65 yr, received i.v. Granisetron 2.5 mg or ramosetron 0.3 mg (n = 60 each) at the end of surgery. A standard general anesthetic technique and postoperative analgesia were used. The incidence of a complete response, defined as no PONV and no need for another rescue medication, 0-3 h after anesthesia was 87% with Granisetron and 90% with ramosetron; the corresponding incidence 3-24 h after anesthesia was 85% and 90%; the corresponding incidence 24-48 h after anesthesia was 70% and 92% (P < 0.05). No clinically serious adverse events due to the drugs were observed in any of the groups. In conclusion, prophylactic therapy with ramosetron is more effective than Granisetron for the longterm prevention of PONV after major gynecologic surgery. IMPLICATIONS We compared the efficacy of Granisetron and ramosetron for preventing postoperative nausea and vomiting in major gynecologic surgery. Prophylactic therapy with ramosetron was more effective than Granisetron for preventing postoperative nausea and vomiting 24-48 h after anesthesia.
-
prophylactic antiemetic therapy with Granisetron dexamethasone combination in women undergoing breast surgery
Acta Anaesthesiologica Scandinavica, 1998Co-Authors: Yoshitaka Fujii, Hiroyoshi Tanaka, Hidenori ToyookaAbstract:Background: Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. This study was undertaken to evaluate the efficacy of Granisetron-dexamethasone combination for the prevention of postoperative nausea and vomiting (PONV) in female patients undergoing general anaesthesia for breast surgery. Methods: In a randomized, double-blind manner, 135 ASA I patients, aged 40–65 years, were assigned to receive placebo (saline), Granisetron 40 μg · kg−1 or Granisetron 40 μg · kg−1 plus dexamethasone 8 mg i.v. (n=45 of each) immediately before the induction of anaesthesia. A standard general anaesthetic technique and postoperative analgesia were used. The PONV and safety assessments were performed continuously during the first 3 h (0–3 h) and the next 21 h (3–24 h) after anaesthesia. Results: A complete response, defined as no PONV and no administration of rescue antiemetic medication, during 0–3 h after anaesthesia was 51%, 82% and 96% in patients who had received placebo, Granisetron and Granisetron-dexamethasone combination, respectively; the corresponding incidence during 3–24 h after anaesthesia was 56%, 84% and 98% (P<0.05; overall Fisher's exact probability test). No clinically important adverse events were observed in any of the groups. Conclusion: Prophylactic use of Granisetron-dexamethasone combination is more effective than Granisetron alone for the prevention of PONV after breast surgery.
-
anti emetic efficacy of prophylactic Granisetron droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy a randomized double blind placebo controlled trial
European Journal of Anaesthesiology, 1998Co-Authors: Yoshitaka Fujii, Hiroyoshi Tanaka, Y Saitoh, Hidenori ToyookaAbstract:This study evaluates the prophylactic anti-emetic efficacy of Granisetron, droperidol and metoclopramide, for the prevention of post-operative nausea and vomiting in female patients undergoing elective laparoscopic cholecystectomy. The patients were randomly assigned to one of four groups ( n =30 for each group): Granisetron 3 mg, droperidol 1.25 mg, metoclopramide 10 mg and placebo (saline). These medications were given immediately before the induction of anaesthesia. During the first 24 h after an-aesthesia, the incidence of post-operative nausea and vomiting was 13, 30, 33 and 37% after administration of Granisetron, droperidol, metoclopramide and placebo, respectively ( P >0.05, overall Fisher's exact probability test). No clinically important adverse effects were observed in either group. Our results suggest that Granisetron is a better anti-emetic than droperidol or metoclopramide for the prevention of post-operative nausea and vomiting after laparoscopic cholecystectomy when compared with a placebo.
Steven M Grunberg - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of transdermal Granisetron for the control of chemotherapy induced nausea and vomiting associated with moderately and highly emetogenic multi day chemotherapy a randomized double blind phase iii study
Supportive Care in Cancer, 2011Co-Authors: Ralph V Boccia, Lucio N Gordan, Gemma Clark, Julian D Howell, Steven M GrunbergAbstract:Purpose A novel transdermal formulation of Granisetron (the Granisetron transdermal delivery system (GTDS)) has been developed to deliver Granisetron continuously over 7 days. This double-blind, phase III, non-inferiority study compared the efficacy and tolerability of the GTDS to daily oral Granisetron for the control of chemotherapy-induced nausea and vomiting (CINV).
Louise Yelle - One of the best experts on this subject based on the ideXlab platform.
-
use of dexamethasone and Granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy national cancer institute of canada clinical trials group
Journal of Clinical Oncology, 1998Co-Authors: Jean Latreille, J L Pater, Dianne Johnston, Francis Laberge, D Stewart, James J Rusthoven, Paul Hoskins, B Findlay, Elissa Mcmurtrie, Louise YelleAbstract:PURPOSETo evaluate the roles of Granisetron and dexamethasone for emesis control on days 2 through 7 after the administration of cisplatin in doses of 50 mg/m2 or greater to patients who had not previously received chemotherapy.PATIENTS AND METHODSFour hundred thirty-five eligible and assessable patients were randomized to one of two arms in a double-blind fashion: arm A; Granisetron 3 mg intravenous (i.v.) plus dexamethasone 10 mg i.v. prechemotherapy followed by Granisetron 1 mg orally at 6 and 12 hours, then Granisetron 1 mg orally and dexamethasone 8 mg orally twice daily on days 2 through 7 (219 patients); arm B; as in arm A but with placebo substituted for Granisetron on days 2 through 7 (216 patients). All patients completed diaries in which episodes of emesis and severity of nausea were recorded.RESULTSThe addition of Granisetron on days 2 through 7 had no discernable impact on nausea and vomiting during this period.CONCLUSIONThe administration of a 5-hydroxytryptamine3, receptor (5-HT3) antagonis...
-
dexamethasone improves the efficacy of Granisetron in the first 24 h following high dose cisplatin chemotherapy
Supportive Care in Cancer, 1995Co-Authors: Jean Latreille, Francis Laberge, James J Rusthoven, Paul Hoskins, Elissa Mcmurtrie, Louise Yelle, Dave Stewart, David Warr, David Walde, F A ShepherdAbstract:The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist Granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of Granisetron after 24 h reduces the occurrence of delayed emesis. This randomised, double-blind, multicentre, three-arm study was conducted at 21 medical centres. A group of 292 nausea- and emcsis-free patients with cancer, who had never had chemotherapy and were scheduled to receive at least 50 mg/m2 cisplatin, were given 3 mg Granisetron i.v. in a 15-min infusion with or without 10 mg dexamethasone i.v. completed 5 min prior to high-dose cisplatin and 1 mg Granisetron p.o. at +6 h and +12 h. Primary study end-points were control of emesis and nausea. Patients completed a self-report diary every 6 h for the first 24 h. At the end of the 24-h period, the patients who received dexamethasone had a significantly higher complete protection rate from emesis (64% compared to 39%) than those who received no steroid. Similarly, the dexamethasone-treated group had a significantly higher complete plus partial (0–2 emetic episodes) protection rate (84% compared to 64%). This study shows that dexamethasone markedly enhances the antiemetic efficacy of Granisetron for acute-onset emesis in high-dose cisplatin chemotherapy.
